Beth C. Seidenberg - 12 Feb 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role: Director, 10%+ Owner
Signature: By: /s/ Ryan Jones, as Attorney-in-Fact
Issuer symbol: KYTX
Transactions as of: 12 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 14 Feb 2024, 18:56:43 UTC
Previous filing: 07 Feb 2024
Next filing: 17 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYTX	Common Stock	Conversion of derivative security		+3,787,940			3,787,940	12 Feb 2024	See Footnote	F1, F2
transaction	KYTX	Common Stock	Conversion of derivative security		+735,984			735,984	12 Feb 2024	See Footnote	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYTX	Series A-1 Redeemable Convertible Preferred Stock	Conversion of derivative security	$0	-4,401,771	-100%	$0.000000^*	0	12 Feb 2024	Common Stock	967,188		See Footnote	F2, F4
transaction	KYTX	Series A-2 Redeemable Convertible Preferred Stock	Conversion of derivative security	$0	-8,830,901	-100%	$0.000000^*	0	12 Feb 2024	Common Stock	1,940,388		See Footnote	F2, F4
transaction	KYTX	Series B Redeemable Convertible Preferred Stock	Conversion of derivative security	$0	-4,006,624	-100%	$0.000000^*	0	12 Feb 2024	Common Stock	880,364		See Footnote	F2, F4
transaction	KYTX	Series B Redeemable Convertible Preferred Stock	Conversion of derivative security	$0	-3,349,538	-100%	$0.000000^*	0	12 Feb 2024	Common Stock	735,984		See Footnote	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
F2	Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any.
F3	Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any.
F4	The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.